This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Biotech M&A has been disappointing. Perhaps the trend will improve before we reach the holidays, but I can only opine on what’s transpired, and honestly, that’s not much.
By my count, there have been 35 transactions totaling $45 billion. My M&A list might differ from others, but I tried to capture all the meaningful activity, year to date.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
